Literature DB >> 35135165

Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.

Randy F Sweis1, Brian Heiss1, Jeremy Segal1, Lauren Ritterhouse1, Sabah Kadri1, Jane E Churpek1, Kenisha Allen1, Dawn Conway1, Carolyn Marinier, Norm D Smith1, Sean P Pitroda1, Walter M Stadler1.   

Abstract

Entities:  

Year:  2018        PMID： 35135165     DOI： 10.1200/PO.18.00264

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  2 in total

Review 1.  Genomics and Immunomics in the Treatment of Urothelial Carcinoma.

Authors:  Veronica Mollica; Francesco Massari; Alessandro Rizzo; Roberto Ferrara; Arjun K Menta; Jacob J Adashek
Journal:  Curr Oncol       Date:  2022-05-12       Impact factor: 3.109

2.  Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.

Authors:  Elżbieta Złowocka-Perłowska; Aleksandra Tołoczko-Grabarek; Steven A Narod; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2022-04-08       Impact factor: 2.857
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.